Methods and compositions for regulating SRCA2A expression levels in myocardial infarction
First Claim
1. A method for increasing sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) gene expression in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutically effective amount of an aromatic-cationic peptide, wherein the aromatic-cationic peptide comprises D-Arg-2′
- 6′
-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof, wherein the subject has suffered a myocardial infarction.
5 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.
6 Citations
10 Claims
-
1. A method for increasing sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) gene expression in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutically effective amount of an aromatic-cationic peptide, wherein the aromatic-cationic peptide comprises D-Arg-2′
- 6′
-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof, wherein the subject has suffered a myocardial infarction. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 6′
Specification